Rocket One Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robbie Knie
- Full Time Employees
- 2
- Sector
- Technology
- Industry
- Software - Infrastructure
- Address
- 720 Monroe Street Hoboken NJ United States of America 07030
- IPO Date
- Feb 15, 2019
- CIK
- 0001711786
- Website
- rocketone.space
- Similar Companies
- Business
- Rocket One Inc. RKTO operates as a space economy-focused company evolving from its former biotech identity, with headquarters in the United States and operations spanning key aerospace and satellite-related markets. It positions itself to develop and commercialize hardware and related services for satellites, defense platforms, and space-enabled AI systems, signaling a strategic pivot toward Orbital Economy activities rather than traditional biotechnology. Main products and services - Space hardware and components: nanoscale and advanced hardware tailored for satellites and space platforms, including specialized AI-enabled systems designed for high-radiation and low-power environments - Nanomagnetic AI chip technology: exclusive rights to nanomagnetic AI chips aimed at ultra-low-power computing in satellite and defense contexts - Satellite and space-system integration support: engineering, integration, and potentially testing services to enable deployment of orbital assets - Defense and intelligence system enablement: hardware platforms designed to support space-based defense and related AI applications Latest major changes - Corporate rebranding and strategic shift: Hoth Therapeutics rebrands to Rocket One Inc. and adopts the RKTO ticker, signaling a transition from biotech to space-oriented hardware and orbital economy initiatives - Ticker and listing transition: begins trading under RKTO on Nasdaq, marking a formal reorientation of capital markets visibility and investor communications toward space-focused business lines - Strategic focus on orbital economy expansion: moves from traditional biotechnology toward satellite hardware, space AI systems, and defense-oriented space platforms - Intellectual property emphasis: secures exclusive rights to nanomagnetic AI chip technology designed for space applications, reinforcing technical moat for future product lines Industry context and segments - Industry: aerospace and defense hardware for space applications; orbital economy - Segments: satellite hardware manufacturing, space-grade AI computing platforms, defense platform integration, and related engineering services - Customer types: satellite operators, government and defense agencies, space infrastructure developers, and commercial space enterprises Geographic operations and corporate structure - Headquarters: United States - Operational footprint: global, with emphasis on markets in North America and international collaborations for satellite and defense infrastructure - Subsidiaries/affiliates: corporate restructuring indicates a shift away from biotech subsidiaries toward space-focused entities or partnerships to support orbital activities Founding and corporate relationships - Founding year: originally established as a biotechnology company; current strategic direction reflects a rebranding and repositioning rather than a simple name change - Parent/affiliates: reorganization implies new corporate architecture aligned with space economy objectives; independent status as Rocket One Inc. under the RKTO ticker Notes - Company communications emphasize a transition to the orbital economy with a focus on space hardware and AI-enabled systems, supported by exclusive nanomagnetic AI chip technology, positioning RKTO within the space industry’s hardware and defense-adjacent segments. - Investors should monitor regulatory filings and Nasdaq disclosures for updates on strategic milestones, partnerships, and product demonstrations as RKTO continues its repositioning in the space sector.
Rocket One Expands AI Infrastructure Platform Through Strategic Partnership with Placeve to Advance Defense, Space, and Intelligent Edge Computing
Short Interest in Rocket One Inc. Common Stock (NASDAQ:RKTO) Decreases By 36.3%
Rocket One Adds SpaceXAI API to Its AI Technology Stack, Advancing Next-Generation Space and Defense Computing
Rocket One Regains Full Nasdaq Compliance with Minimum Bid Price Requirement
Rocket One Launches Swarm Stage AI™ to Counter Autonomous Drone Swarms
Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets
Space Stocks Get Torched: Short Seller Calls Them 'Sci-Fi Wishes'
ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.) TO SPACE AND DEFENSE ADVISORY BOARD
ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.
Rocket One Appoints Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology
Rocket One Appoints Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology
Why Hoth Therapeutics (HOTH) Stock Is Surging After Hours Today
Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications
Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform
AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering